Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis

BACKGROUND: Although combination therapy with 5 alpha-reductase inhibitor (5ARI) and alpha-blocker is one of the standard interventions in symptomatic benign prostatic hyperplasia (BPH), 5ARI monotherapy is seldom the focus of attention. Adverse events associated with 5ARI include depression and sui...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jae Heon, Baek, Min Jung, Sun, Hwa Yeon, Lee, Bora, Li, Shufeng, Khandwala, Yash, Del Giudice, Francesco, Chung, Benjamin I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169865/
https://www.ncbi.nlm.nih.gov/pubmed/30281615
http://dx.doi.org/10.1371/journal.pone.0203479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169865/
https://www.ncbi.nlm.nih.gov/pubmed/30281615
http://dx.doi.org/10.1371/journal.pone.0203479

Ejemplares similares